Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alessandro Gozzetti

Showing results (141-150 of 212) with videos related to

Pageof 22
Sort By:
Frontiers in Medicine|August 28, 2020
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE ProtocolEnrico Capochiani, Bruno Frediani, Giorgio Iervasi, et al.
Hemasphere|January 29, 2026
IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemiaRosita Del Prete, Vjola Tusha, Helga Simon-Molas, et al.
Apoptosis : an International Journal on Programmed Cell Death|July 4, 2026
Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4Vanessa Tatangelo, Gabriele Carullo, Ludovica Lopresti, et al.
American Journal of Hematology|March 16, 2017
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphomaFrancesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 5, 2024
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patientsSara Rossi, Vanessa Tatangelo, Maria Dichiara, et al.
American Journal of Hematology|August 28, 2014
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyPaola Tacchetti, Carolina Terragna, Monica Galli, et al.
American Journal of Clinical Pathology|November 23, 2017
Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From SenegalTeresa Amato, Abibatou Sall, Tandakha NDiaye Dièye, et al.
Cell Death & Disease|February 15, 2024
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemiaGioia Boncompagni, Vanessa Tatangelo, Ludovica Lopresti, et al.
Leukemia & Lymphoma|March 18, 2021
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational studyIlaria Rizzello, Michele Cavo, Luca Dozza, et al.
Pageof 22

Showing results (141-150 of 212) with videos related to

Sort By:
Pageof 22
Frontiers in Medicine|August 28, 2020
Ruxolitinib Rapidly Reduces Acute Respiratory Distress Syndrome in COVID-19 Disease. Analysis of Data Collection From RESPIRE ProtocolEnrico Capochiani, Bruno Frediani, Giorgio Iervasi, et al.
Hemasphere|January 29, 2026
IL21-STAT3 controls the pentose phosphate pathway to support metabolic reprogramming and tumor progression in chronic lymphocytic leukemiaRosita Del Prete, Vjola Tusha, Helga Simon-Molas, et al.
Apoptosis : an International Journal on Programmed Cell Death|July 4, 2026
Taginostat, a new quinolone-based HDAC6 inhibitor, promotes apoptosis of chronic lymphocytic leukemia cells in vitro and in vivo by activating STAT4Vanessa Tatangelo, Gabriele Carullo, Ludovica Lopresti, et al.
American Journal of Hematology|March 16, 2017
Factors predicting survival in chronic lymphocytic leukemia patients developing Richter syndrome transformation into Hodgkin lymphomaFrancesca Romana Mauro, Piero Galieni, Alessandra Tedeschi, et al.
Annals of Hematology|August 3, 2017
Similar survival outcomes in patients with biclonal versus monoclonal myeloma: a multi-institutional matched case-control studyArtur Jurczyszyn, Alessandro Gozzetti, Joanna Gdula-Argasińska, et al.
Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie|April 5, 2024
A novel potent class I HDAC inhibitor reverses the STAT4/p66Shc apoptotic defect in B cells from chronic lymphocytic leukemia patientsSara Rossi, Vanessa Tatangelo, Maria Dichiara, et al.
American Journal of Hematology|August 28, 2014
Bortezomib- and thalidomide-induced peripheral neuropathy in multiple myeloma: clinical and molecular analyses of a phase 3 studyPaola Tacchetti, Carolina Terragna, Monica Galli, et al.
American Journal of Clinical Pathology|November 23, 2017
Preferential Usage of Specific Immunoglobulin Heavy Chain Variable Region Genes With Unmutated Profile and Advanced Stage at Presentation Are Common Features in Patients With Chronic Lymphocytic Leukemia From SenegalTeresa Amato, Abibatou Sall, Tandakha NDiaye Dièye, et al.
Cell Death & Disease|February 15, 2024
Leukemic cell-secreted interleukin-9 suppresses cytotoxic T cell-mediated killing in chronic lymphocytic leukemiaGioia Boncompagni, Vanessa Tatangelo, Ludovica Lopresti, et al.
Leukemia & Lymphoma|March 18, 2021
Subcutaneous bortezomib-containing regimens as up-front treatment of newly diagnosed transplant-eligible multiple myeloma patients: a retrospective, non-interventional observational studyIlaria Rizzello, Michele Cavo, Luca Dozza, et al.
Pageof 22